Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Launched by THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY · Aug 26, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Letermovir, which is being tested to help prevent Cytomegalovirus (CMV) infection in patients who are about to receive a hematopoietic stem cell transplant (HSCT). CMV is a common virus that can cause serious problems for people with weakened immune systems, such as those undergoing this type of transplant. The trial is looking for candidates who have chosen to proceed with their transplant and have undergone a specific test called mNGS to detect any potential infections before the procedure.

To be eligible for the study, participants need to be between 14 and 65 years old, and they should not have any active infections when starting Letermovir. Additionally, those currently involved in another anti-CMV study or who have taken similar medications before cannot participate. If accepted into the trial, participants will receive Letermovir and will be monitored closely to see how well it prevents CMV infection during their recovery. This study is currently recruiting participants, and it aims to improve safety and outcomes for HSCT recipients facing the risk of CMV.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • HSCT candidate who has decided to primary transplant and is willing to participate in the study.
• • HSCT candidate undergo mNGS detection before transplantation.
• Exclusion Criteria:
• • Patients below 14 years ago or above 65 years ago.
• • Patients having active infection at the time of letermovir initiation.
• • Patient recruited in a clinical study on an anti-CMV trial, or took similar anti-CMV drugs previously.